A federal regulatory crackdown on Hims could impact a broader network of compounding pharmacies and telehealth companies.

Hims & Hers Health shares fell in extended trading after the company reported second-quarter results that missed Wall Street's expectations for revenue. Revenue increased 73% year over year to $544.8 ...

CHONGQING, CHINA - MAY 04: In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen, with the company's stock market performance and candlestick chart ...

Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. The company is building a moat through personalized medicine, vertical integration, and diversification ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses lately. The San Francisco, CA-based health and wellness platform’s stock has lost 39.2% compared with the ...

HIMS is upgraded to a speculative Buy after the steep correction, with the cheaper valuations offering a much-needed, improved margin of safety. Robust subscription/ARPU growth, international ...